Duitse aandelen « Terug naar discussie overzicht

Bayer 2022 Jaardraadje!

475 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 ... 20 21 22 23 24 » | Laatste
4finance
1
quote:

Zengty schreef op 10 februari 2022 08:59:

Bayer gets U.S. FDA Fast Track designation for asundexian Stroke Program.Drug is potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke
Mooi! Nu op naar de €60 en hoger ;-)

N audio
1
Nou, ik ga vaker mopperen. ;) Dat was leuk wakker worden deze ochtend.
Zengty bedankt voor de link, wederom goed nieuws voor Bayer.
LL
1
EXCLUSIVE-Bayer revives plan to introduce new GM cotton seeds in India

NEW DELHI, Feb 10 (Reuters) - Germany's Bayer BAYGn.DE has applied to cultivate its next generation of genetically modified (GM) cotton seeds in India, government sources said, reviving plans to bring the high-yielding, herbicide-tolerant variety to the country.

In late 2016, Monsanto withdrew an application seeking approval from New Delhi for the GM variety Bollgard II Roundup Ready Flex (RRF), to protest a raft of government measures against the world's biggest seed maker.

Bayer, which bought Monsanto in 2018 for $63 billion, has resubmitted the application for Bollgard II RRF, signalling reviving interest from foreign seed, agricultural chemicals and farm technology companies in India, the world's leading producer of cotton, rice, wheat and an array of other farm goods.

After Monsanto's row with India over pricing and intellectual property rights, other global corporations in the agriculture industry decided to scale back investments and put off plans to introduce new seed varieties and farming technologies in India.

Bayer resubmitted the application seeking cultivation of the Bollgard II RRF variety in December, said the sources, who asked not to be identified in line with official rules.

"Bayer, through its local joint venture partner, has resubmitted the dossier for seeking regulatory approvals to introduce RRF in India," said one of the government sources familiar with the matter.

"Once the regulatory approval process starts, it might take a few years for Bayer to get the final approval."

It was not clear when the approval process would start, the sources said.

"Our efforts are aimed at enhancing crop productivity, contributing towards doubling farmer incomes and making Indian agriculture sustainable and globally competitive," Bayer said in an emailed statement to Reuters.

The GM cotton seed variety could cut the cost of cultivation in India, boost crop yields and act as an antidote to the pink bollworm pest, farm policy experts said.

The pink bollworm pest has of late become a major threat to India's cotton crop. The pest attack has also hit farmers' income, with nearly 20% to 30% of the country's 12 to 13 million hectares of the cotton area infested with pink ballworm, based on estimates from industry bodies and farmers.

DATED TECHNOLOGY

India first allowed GM cotton cultivation in 2002 by approving Monsanto's single gene Bollgard I technology, and Monsanto's GM cotton seed technology soon dominated 90% of India's cotton acreage. Apart from GM cotton, India has not approved any other transgenic crop.

New Delhi approved Monsanto's double gene Bollgard II in 2006, helping to transform India into the world's No.1 cotton producer and second-largest exporter of the fibre as output jumped fourfold. India had previously been a net importer of cotton.

But crop yields have stagnated since then and farmers say the existing variety is losing its effectiveness and becoming more vulnerable to pests such as pink bollworm.

"In the absence of a new variety, Indian farmers are forced to rely on a dated technology," the head of a global seed company said requesting anonymity.

"While India has dragged its feet, other producers have adopted newer cotton seed technologies over the past 15 years."

The other major attraction for farmers is the convenience of weed management, said Bhagirath Choudhary, director of the South Asia Biotech Centre, an organisation for the promotion of biotechnology. Asia Biotech Society lists many government-run scientific research bodies and private companies, including Bayer as its research partners.

"The RRF variety can significantly bring down the cost of cultivation for millions of India's poor, small farmers as the cost of labour for removing unwanted vegetation and picking weeds alone accounts for 65% of the total cost of cotton cultivation in the country," Choudhary said.
4finance
1
quote:

N audio schreef op 14 februari 2022 10:20:

Deze morgen mijn positie met een kwart uitgebreid. Nu volledig.
Mooi. Sterk overdreven daling vandaag.
Succes.

stockholder
1
Prima cijfers van DSM. Misschien niet helemaal vergelijkbaar maar moet toch een indicatie zijn dat ook Bayer goed gedraaid heeft.
4finance
1
quote:

stockholder schreef op 15 februari 2022 11:19:

Prima cijfers van DSM. Misschien niet helemaal vergelijkbaar maar moet toch een indicatie zijn dat ook Bayer goed gedraaid heeft.
Dat verwacht ik ook. Bayer vandaag weer "in herstel"

N audio
0
4finance
2
quote:

N audio schreef op 18 februari 2022 09:21:

Vanochtend weer goed nieuws rondom een medicijn van Bayer tegen kanker...
De BAYER goed nieuws show komt op gang ;-)

Nu eerst maar op naar de €60,00

LL
1
Bayer lifts peak sales estimate for prostate cancer drug

By Ludwig Burger and Patricia Weiss

FRANKFURT, Feb 18 (Reuters) - A therapy mix including Bayer's Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the drugmaker to boost sales estimates for the product.

Nubeqa, when combined with standard therapy, reduced the risk of dying during the trial period by 32.5% in a comparison to standard therapy alone, the German company said in a statement on Thursday, citing trial results.

As a result, Bayer said it now expected more than 3 billion euros ($3.4 billion) in sales from the product in its best year, up from a previous target of more than $1 billion, making Nubeqa the most promising growth driver at Bayer's drugs division.

Nubeqa, also known as darolutamide, is jointly developed with Finnish drugmaker Orion and the partner company's stock soared 22.7% at the 0800 GMT market open, while Bayer shares gained 1.9%.

Bayer, which is paying billions to settle U.S. claims its Roundup weedkiller caused cancer, needs to strengthen its drug development pipeline as its two pharmaceutical best-sellers, stroke prevention pill Xarelto and eye drug Eylea, face a decline in sales in a few years.

Nubeqa is already approved in non-metastatic prostate cancer that cannot be treated with standard hormone therapy, and the new results point to a larger market opportunity if regulators clear the wider use.

The drug is one of three Bayer pharmaceuticals that the company expects to generate more than $1 billion in peak annual sales, known in the industry as blockbusters, alongside kidney disease treatment finerenone and menopausal symptoms relief elinzanetant.

The trial's overall success was announced in December and detailed results were published in The New England Journal of Medicine on Thursday.

($1 = 0.8797 euros)

(Editing by Miranda Murray. Editing by Jane Merriman)

((ludwig.burger@thomsonreuters.com; +49 30 220133634))
stockholder
0
Het leek een mooie dag te worden voor de koers van Bayer. Helaas zakt de hele handel vanmiddag weer terug.
We kunnen wel constateren dat de ondertoon voor Bayer goed is. Beloofd wat voor de cijfers op 1 maart as
4finance
0
quote:

stockholder schreef op 18 februari 2022 19:17:

Het leek een mooie dag te worden voor de koers van Bayer. Helaas zakt de hele handel vanmiddag weer terug.
We kunnen wel constateren dat de ondertoon voor Bayer goed is. Beloofd wat voor de cijfers op 1 maart as
Ik heb net voor het sluiten flink bijgekocht door een andere long positie te verkopen. BAYER staat aan de vooravond van een periode van stijgen met al deze goede berichten.

4finance
0
quote:

jowi schreef op 18 februari 2022 09:23:

Idd gaat goed. Plus 2,7 % € 55,44
Deze koers komt er komende week vast wel gezien de mooie berichten.

4finance
0
BAYER, prachtige vooruitzichten en het daalt weer hard....
Maar weer op onze handen zitten.

LL
0
quote:

4finance schreef op 22 februari 2022 00:50:

BAYER, prachtige vooruitzichten en het daalt weer hard....
Maar weer op onze handen zitten.
Nog een weekje met korting kopen. Volgende week de jaarcijfers!
N audio
0
Ik heb niet op mijn handen gezeten.
Stukje verlies genomen op een klein deel van de porto. Dit deel vanochtend omgezet bij opening in Bayer.
Ik ben wel benieuwd naar de cijfers.

4finance
1
quote:

N audio schreef op 22 februari 2022 09:14:

Ik heb niet op mijn handen gezeten.
Stukje verlies genomen op een klein deel van de porto. Dit deel vanochtend omgezet bij opening in Bayer.
Ik ben wel benieuwd naar de cijfers.

Mooi! Bayer zou toch flink moeten herstellen met alle positieve berichten.
Eerst maar eens de €60 grens opzoeken.

stockholder
2
quote:

N audio schreef op 22 februari 2022 09:14:

Ik heb niet op mijn handen gezeten.
Stukje verlies genomen op een klein deel van de porto. Dit deel vanochtend omgezet bij opening in Bayer.
Ik ben wel benieuwd naar de cijfers.

Soms moet je inderdaad de bakens verzetten. Hoort bij een goede handelsgeest
475 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 ... 20 21 22 23 24 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
874,85  +8,34  +0,96%  12:33
 Germany40^ 18.043,30 +1,02%
 BEL 20 3.883,63 +0,53%
 Europe50^ 4.985,32 +0,98%
 US30^ 38.305,01 +0,14%
 Nasd100^ 17.268,11 +0,34%
 US500^ 5.023,96 +0,14%
 Japan225^ 37.628,71 -0,25%
 Gold spot 2.299,87 -1,18%
 EUR/USD 1,0657 +0,05%
 WTI 81,75 -0,37%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

VIVORYON THER... +29,82%
ALLFUNDS GROUP +4,13%
PROSUS +4,02%
JUST EAT TAKE... +3,69%
Philips Konin... +2,64%

Dalers

RANDSTAD NV -5,88%
Akzo Nobel -5,08%
NSI -3,67%
ArcelorMittal -1,74%
AMG Critical ... -1,62%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront